

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.:	SERIAL NO.:	
				CV01148KB	10/777,849	
				APPLICANT:		
				Chackalamannil et al.		
				FILING DATE:	GROUP:	
				02/12/2004	1624	
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AB	5,250,534	10/05/1993	Bell et al.	514	258	
AC	5,256,768	10/26/1993	Coughlin	530	327	
AD	5,321,029	08/14/1994	Maschler et al.	514	263.36	
AE	5,346,901	09/13/1994	Bell et al	514	258	
AF	5,393,755	02/28/1995	Neustadt et al.	514	233.2	
AG	5,409,934	04/26/1995	Smith et al.	514	263.33	
AH	5,470,579	11/28/1995	Bonte et al.	424	450	
AI	5,837,693	06/10/1997	Porter et al.	514	227	
AJ	5,888,768	11/18/1997	Coughlin et al	514	15	
AK	5,719,283	02/17/1998	Bell et al	544	262	
AL	5,769,994	06/02/1998	Coughlin et al	514	9	
AM	5,798,248	08/28/1998	Coughlin et al	435	214	
AN	5,824,683	10/20/1998	McKittrick et al	514	257	
AO	6,856,448	01/05/1999	Coughlin	530	388.22	
AP	6,859,006	01/12/1999	Daugan	514	249	
AQ	5,874,437	02/23/1999	Garvey et al	514	258	
AR	5,877,216	03/02/1999	Place et al	514	257	
AS	5,939,419	08/17/1999	Tulshian et al	544	262	
AT	5,955,611	09/21/1999	Dunn et al.	514	253	
AU	5,858,926	09/28/1999	Garvey et al	514	250	
AV	5,981,527	11/09/1999	Daugan et al	514	450	
AW	5,981,563	11/09/1999	Lowrey, Fred	607	2	
AX	6,023,640	02/08/2000	Ross, Jesse	424	1,48	
AY	6,024,936	02/16/2000	Coughlin et al	546	84	
AZ	6,025,494	02/15/2000	Daugan	514	258	
BA	6,037,346	03/14/2000	Doherty, Jr. et al	514	450	
BB	6,051,594	04/18/2000	Lowrey, Fred	544	371	
BC	6,066,735	05/23/2000	Dunn et al.	514	252.16	
BD	6,087,382	07/11/2000	El-Rashidy, Ragab	514	268	
BE	6,100,270	08/08/2000	Campbell	435	7.1	
BF	6,124,101	09/26/2000	Coughlin	514	250	
BG	6,140,329	10/31/2000	Daugan	514	249	
BH	6,143,748	11/07/2000	Daugan et al	514	69.1	
BI	6,197,541 B1	03/08/2001	Coughlin	435	218	
BJ	6,362,178 B1	03/26/2002	Niewöhner et al	514	256	
BK	6,403,597 B1	08/11/2002	Wilson et al	514	258	
BL	6,469,012 B1	10/22/2002	Ellis et al	514	262	
BM	6,469,016 B1	10/22/2002	Place et al	514	573	
BN	6,472,434 B1	10/29/2002	Place et al	514	427	
BO	6,512,002 B2	01/28/2003	Lee et al	514		

1/8/05

Sue L. B./bjs

Page 2 of 6

FOREIGN PATENT DOCUMENTS					CLASS	SUB-CLASS	TRANSLATION	
CA	DOCUMENT NUMBER	DATE	COUNTRY				YES	NO
CC	EP 0 258 191 A1	02.03.88	EPO					
CD	EP 0 389 282 A2	26.09.90	EPO					
CE	EP 0 463 758 A1	02.01.92	EPO					
CF	EP 0 389 282 A2	26.09.90	EPO					
CG	EP 0 389 282 A3	26.09.90	EPO					
CH	EP 0 389 282 B1	26.09.90	EPO					
CI	0 389 282 A2	26.09.90	EPO					
CJ	0 463 758 B1	02.01.92	EPO					
CK	0 526 004 A1	03.02.93	EPO					
CL	0 702 565 B1	27.03.96	EPO					
CM	WO 92/11260	07.1992	PCT					
CN	WO 91/19717	26.12.91	PCT					
CO	WO 91/07945	13.06.91	PCT (in French)					
CP	WO 91/07945 A1	13.06.91	PCT (English Translation)				X	
CQ	WO 92/05176	02.04.92	PCT					
CR	WO 92/11260	09.07.92	PCT					
CS	WO 93/23401	25.11.93	PCT					
CT	P 19 38 018.6	28.01.71	Germany					
CU	WO 94/28902	22.12.94	PCT					
CV	WO 99/54331	02.04.92	PCT (in German)					
CW	WO 99/54331	28.10.99	PCT (English Translation)				X	
CX	WO 92/05175	02.04.92	PCT					
CY	WO 99/62905	09.12.99	PCT					
CZ	WO 99/24433	20.05.99	PCT					
DA	FR 2.116.302	13.07.72	France					
DB	89/10123	02.11.89	WIPO					
DC	91/18717	26.12.91	WIPO					
DD	92/05175	02.04.92	WIPO					
DE	92/05178	02.04.92	WIPO					
DF	93/23401	25.11.93	WIPO					
DG	94/19351	01.09.94	WIPO					
DH	98/16644	06.06.96	WIPO					
DI	86/16857	06.06.96	WIPO					
DJ	96/32379	17.10.98	WIPO					
DK	97/03985	06.02.97	WIPO					
DL	97/24334	10.07.97	WIPO					
DM	97/43267	20.11.97	WIPO					
DN	98/08848	05.03.98	WIPO					
DO	98/15530	16.4.98	WIPO					
DP	98/38168	03.09.98	WIPO					
DQ	98/49166	06.11.98	WIPO					
DR	99/00369	07/01/99	WIPO					
DS	99/00373	07/01/99	WIPO					
DT	99/21558	08.05.99	WIPO					
DU	99/21831	08.05.99	WIPO					
DV	99/42452	28.08.99	WIPO					
DW	99/43674	02.09.99	WIPO					
DX	99/43679	02.09.99	WIPO					
DY	99/54333	28.10.99	WIPO					

*Searcher B/L*

1/8/05

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
SW	EA Ho-Sam Ahn et al, "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity", <i>J. Med. Chem.</i> , Vol. 40, No. 14, pp. 2196-2210 (1997).
	EB J.L. Ambros et al, "Studies on Vasoocclusive Crisis of Sickle Cell Disease. I. Effect of Pentoxyfylline", <i>Journal of Medicine</i> , Vol. 10, No. 6, pp. 445-456 (1979).
	EC Bradley D. Anderson et al, "Preparation of Water-Soluble Compounds Through Salt Formation", <i>The Practice of Medicinal Chemistry</i> , C. G. Wermuth, Ed., Academic Press, New York, pp. 739-754 (1998).
	ED M.I. Angel et al, "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein Kinase Activity and Cyclic Nucleotide Levels", <i>J. Mol. Cell Cardiol</i> , Vol. 12, No. 10, pp. 939-954, Abstract (1980).
	EE Hans-Joachim Arnold et al, "Pharmacopoeia of Traditional Medicine in Venda", <i>Journal of Ethnopharmacology</i> , Vol. 12, pp. 35-74 (1984).
	EF William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", <i>The Journal of Urology</i> , Vol. 145, No. 4, p. 341A, Abstract No. 516 (1991).
	EG Joseph A. Beavo, "Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms", <i>Physiological Reviews</i> , Vol. 75, No. 6, pp. 725-748 (October 1995).
	EH Joseph A. Beavo & David H. Reifanyder, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective Inhibitors", <i>Trends in Pharmacological Sciences</i> , Vol. 11, No. 4, pp. 150-155 (April 1990).
	EI Stephen M. Berge et al, "Pharmaceutical Salts", <i>J. of Pharmaceutical Sciences</i> , Am. Pharm. Assoc. and Pergamon Press, Vol. 66, No. 1, pp. 1-19 (January, 1977).
	EJ Anne Bowman et al, "Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle", <i>Br. J. Pharmac.</i> , Vol. 81, pp. 665-674 (1984).
	EK V. Mironi et al, letter to ed. re. "Intracavernous Cyclic GMP Products Produces Penile Erection in Patients with Erectile Dysfunction", <i>British Journal of Urology</i> , Vol. 71, No. 3, p. 365 (March 1993).
	EL Gary Brooker et al, "Radioimmunoassay of Cyclic AMP and Cyclic GMP", <i>Advances in Cyclic Nucleotide Research</i> , Paul Greengard et al, Eds., Vol. 10, pp. 1-33 (1979).
	EM Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of corpus cavernosum smooth muscle", <i>Ph.D. dissertation U.C.L.A.</i> (UMI Dissertation Services Order No. 9319914) (179 pgs) (1993).
	EN Peggy Bush et al, "Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum", <i>Journal of Urology</i> , Vol. 147, pp. 1650-1655 (June 1992).
	EO S. Carrier et al, "Erectile Dysfunction", <i>Endocrinology and Metabolism Clinics of North America: Clinical Andrology</i> , Vol. 23, No. 4, pp. 773-782 (Dec. 1994).
	EP P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3-Methylflavone-8-carboxylic Acid", <i>Drug. Res.</i> , Vol. 38 (1), No. 3, pp. 379-382 (1988).
	EQ J. Cortijo et al, "Investigation Into the role of Phosphodiesterase IV in Bronchorelaxation, including Studies with Human Bronchus", <i>Br. J. Pharmacol.</i> , Vol. 108, pp. 562-568 (1993).
	ER Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors", <i>Br. J. Pharmacol.</i> , Vol. 106, pp. 1028-1034 (1992).
	ES Dario Doller et al, "The G1F System as a Tool in Medicinal Chemistry: The Oxidation of SCH57726 under GOAGG III Conditions", <i>Inorganic and Medicinal Chemistry Letters</i> , Vol. 7, No. 11, pp. 1381-6 (1997).
	ET Dukarm R.C., et al., (1999) The cGMP-specific Phosphodiesterase Inhibitor E4021 Dilates the Pulmonary Circulation. <i>American Journal Respir. Crit. Care Med.</i> , Volume 160:858-865.
	EU I.J. Fishman, "Treating Erectile Dysfunction: New Approaches", <i>Drug Therapy</i> , Vol. 8, pp. 102-110 (August 1989).
	EV Gaine S.P., et al., (1988) Primary Pulmonary Hypertension, <i>The Lancet</i> , Volume 352:719-725.
	EW P.G. Gillespie & J.A. Beavo, "Inhibition and Stimulation of Photoreceptor Phosphodiesterases by Dipyridamole and M & B 22,848", <i>Molecular Pharmacology</i> , Vol. 36, pp. 773-781 (Nov. 1988)
	EX J.C. Gingell, et al, "Emerging pharmacological therapies for erectile dysfunction", <i>Exp. Opin. Ther. Patents</i> , Vol. 9, No. 12, pp. 1689-1696 (1999).
	EY Philip L. Gould, "Salt Selection for Basic Drugs", <i>Int'l J. of Pharmaceutics</i> , Elsevier, Vol. 33, pp. 201-217 (1986).
	EZ Theodora W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, pp. 1-9 (1981).
	FA Alain Gregoire, "Viagra: on release", <i>BMJ</i> , Vol. 317, p. 759-760 (Sept. 18, 1998).

11/10/8

FB	Hanasaki N., et al., (1998) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Pulmonary Hypertension in Rats, <i>American Journal of Physiol.</i> , Volume 277 (Lung Cell. Mol. Physiol. 21): L225-L232.
FC	"Pharmaceutical Coloring Agents", <i>Handbook of Pharmaceutical Excipients</i> , American Pharmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1986).
FD	Takeru Higuchi, "Prodrug & Drug Delivery - An Overview", <i>Bioreversible Carriers in Drug Design: Theory and Application</i> , Edward B. Roche, Ed., Pergamon Press, New York, pp. 1-12 (1987).
FE	T. Higuchi et al., Eds., "Pro-drugs as Novel Drug Delivery Systems", <i>ACS Symposium Series 14</i> , American Chemical Society, Wash., D.C., pp. 1-115 (1975).
FF	F. Holmquist et al., "Actions of 3-Morpholinosydnonimine (SIN-1) on Rabbit Isolated Penile Erectile Tissue", <i>Journal of Urology</i> , Vol. 150, No. 4, pp. 1310-1315 (Oct. 1993).
FG	F. Holmquist et al., "Effects of the nitric oxide synthase inhibitor N <sup>o</sup> -nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit", <i>Acta Physiol Scand</i> , Vol. 143, pp. 299-304 (1991).
FH	Sue Ellen Jackson et al., "Erectile Dysfunction: Therapy Health Outcomes", <i>Outcomes Research</i> , Pfizer, Inc., Elsevier (Dec. 16, 1997).
FI	T. Katsushima et al., "Structure-Activity Relationships of 8-Cycloalkyl-1,3-diprophyxanthines as Antagonists of Adenosine Receptors", <i>J. Med. Chem.</i> , 1990, 33, pp. 1906-1910.
FJ	Yasuo Kawanishi et al., "Double-Blind Trial of Oral Prostaglandin E, on Impotence", <i>The Japanese Urological Association</i> , Vol. 83, No. 1, Abstract, pp. 1858-1861 (Oct. 1992).
FK	Stanley G. Korenman et al., "Treatment of Vascularogenic Sexual Dysfunction with Pentoxifylline", <i>J. Am. Geriatrics Soc.</i> , Vol. 41, No. 4, pp. 363-366 (April, 1993).
FL	Robert J. Krane et al., "Impotence", <i>New England Journal of Medicine</i> , Vol. 321, No. 24, pp. 1648-1658 (Dec. 14, 1989).
FM	Kremzer, et al., "Synth. & Biol. activity of diprophylline anal.", <i>Khim-Farm. Zh.</i> , 15/6, 59-64 (1981); CAS ABS '81:632818.
FN	W.R. Kukovatz et al., "Evidence for Cyclic GMP-Mediated Relaxant Effects of Nitro-Compounds in Coronary Smooth Muscle", <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , Vol. 310, pp. 129-138 (1979).
FO	Y.- M. Lin et al., "The rabbit as an intracavernous injection study model", <i>Urol. Res.</i> , Vol. 24, pp. 27-32 (1996).
FP	Torn F. Lue, "Topical and Oral Agents for Erectile Dysfunction", <i>J. Formos Med. Assoc.</i> , Vol. 98, No. 4, pp. 233-241 (March 9, 1999).
FQ	James A. Lugg et al., "The Role of Nitric Oxide in Erectile Function", <i>J. of Andrology</i> , Vol. 16, No. 1, pp. 2-4 (Jan./Feb. 1995).
FR	E.G. McMahon et al., "Depressor and Natriuretic Effects of M & B 22,948, a Guanosine Cyclic 3',5'-Monophosphate-Selective Phosphodiesterase Inhibitor", <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 2513, pp. 1000-1005 (1989).
FS	W. Meinhardt et al., "The influence of medication on erectile function", <i>International Journal of Impotence Research</i> , Vol. 9, pp. 17-26 (1997).
FT	M.F. Meyer et al., "Intracavernous Application of SIN-1 in Rabbit and Man: Functional and Toxicological Results", <i>Ann. Urol.</i> , Vol. 27, No. 3, pp. 179-182 (1993).
FU	Alvaro Morales et al., "Oral and Topical Treatment of Erectile Dysfunction", <i>Urologic Clinics of North America</i> , Vol. 22, No. 4, pp. 879-886 (Nov. 1995).
FV	John E. Morley, "Management of Impotence, Diagnostic considerations and therapeutic options", <i>Impotence</i> , Vol. 93, No. 3, pp. 65-67, 71-72 (Feb. 15, 1993).
FW	Murray, K.J., Phosphodiesterase V <sub>A</sub> Inhibitors, <i>DN&amp;P</i> 6(3), pp. 150-155, April 1993.
FX	C. David Nicholson et al., "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", <i>Trends in Pharmacological Sciences</i> , Vol. 12, pp. 19-27 (Jan. 1991).
FY	Nantka-Namirska, P., et al., Syntaza 7-Podstawionych Pochodnych 8-aminometylo-1,3-Dwumetylksantyny, <i>ACIA POLAN, PHARM</i> , XXXI Nr 1, (1974) [in Polish]
FZ	Nantka-Namirska, P., et al., Synthesis of 7-Substituted Deviates of 8-aminomethyl-1,3-dimethylxanthine, <i>Acta Polon. Pharma</i> , 31(1):5-11 (1974) [English Translation]
GA	Ohnishi M., et al., (1999) E4021, a Selective Phosphodiesterase 5 Inhibitor, Potentiates the Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs. <i>Journal of Cardiovascular Pharmacology</i> , Volume 33:619-624.
GB	Elizabeth Palmer, "Making the love drug", <i>Chemistry In Britain</i> , Vol. 35, No. 1, pp. 24-26 (Jan. 1999)
GC	Pfizer, "Erectile Dysfunction", 1998 Annual Report, p. 21.
GD	Physicians' Desk Reference, Medical Economics Company, 56 <sup>th</sup> Ed., pp. 2534-37 (2001)
GE	Physician's Desk Reference, Medical Economics Company, 46th Ed., pp. 1099-1100 (1992).
GF	Physician's Desk Reference, Medical Economics Company, 48th Ed., Product Identification Dayton Hlmin Tablets and Yohimex Tablets, pp. 409, 905 & 1190 (1992)

118705  
SCHERING-PLOUGH

Page 5 of 6

GG	Jacob Rajfer et al, "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission", <i>New England Journal of Medicine</i> , Vol. 326, No. 2, pp. 90-94 (Jan. 9, 1992)
GH	J. Reiser et al, "The Effect of Zaprinast (M&B 22,948, an Orally Absorbed Mast Cell Stabilizer) on Exercise-Induced Asthma in Children", <i>Br. J. Dis. Chest.</i> , Vol. 80, pp. 157-163 (1986)
GI	Remington's Pharmaceutical Sciences, "Coloring, Flavoring and Diluting Agents", 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1288-1300 (1990)
GJ	Remington's Pharmaceutical Sciences, 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1519-1712 (1990)
GK	Alan Riley, "Oral Treatments for Erectile Dysfunction", <i>International Journal of STD &amp; AIDS</i> , Vol. 7, Suppl 3, pp. 16-18 (1996)
GL	N.I. Romanenko et al, "Synthesis and biological activity of 3-methyl, 7- or 8-alkyl-, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines", <i>Chemical Abstracts</i> , 108: 95577n (1986)
GM	Raymond C. Rosen et al, "The process of care model for evaluation and treatment of erectile dysfunction", <i>International Journal of Impotence Research</i> , Vol. 11, pp. 59-74 (1999)
GN	David P. Rotella et al, "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction", <i>J. Med. Chem.</i> , Vol. 43, No. 7, pp. 1257-1263 (2000)
GO	Robin M. Rudd et al, "Inhibition of Exercise-Induced Asthma by an Orally Absorbed Mast Cell Stabilizer (M & B 22,948)", <i>Br. J. Dis. Chest.</i> , Vol. 77, pp. 78-84 (1983)
GP	Richard Sachse et al, "Safety, Tolerability and Pharmacokinetics of Bay 38-9456 In Patients with Erectile Dysfunction", <i>Journal of Urology</i> , Vol. 163, No. 4, p. 204 (May 2000)
GQ	T. Saeki & I. Salto, "Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes from Pig Aorta", <i>Biochemical Pharmacology</i> , Vol. 48, No. 5, pp. 833-839 (1993)
GR	Junichi Shimada et al, "A Convenient Synthesis of Tricyclic Purine Derivatives", <i>J. of Heterocyclic Chemistry</i> , Vol. 30, pp. 241-246, (1993)
GS	Christian G. Stief et al, "Preliminary Results with the Nitric Oxide Donor Linsidomine Chlorhydrate in the Treatment of Human Erectile Dysfunction", <i>The Journal of Urology</i> , Vol. 148, No. 5, pp. 1437-1440 (Nov. 1992)
GT	Christian G. Stief et al, "Preliminary report on the effect of the nitric oxide donor SIN-1 on human cavernous tissue in vivo", <i>World J. Urol.</i> , Vol. 9, pp. 237-239 (1991)
GU	Christian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) Inhibitors on Human and Rabbit Cavernous Tissue in Vitro and in Vivo", <i>J. of Urology</i> , Am. Urological Assoc., Vol. 159, pp. 1390-1393 (1998)
GV	A. Taher et al, "Phosphodiesterase Activity in Human Cavernous Tissue and the Effect of Various Selective Inhibitors", <i>The Journal of Urology</i> , Vol. 149, No. 4, p. 285 (Abstract) (April 1993)
GW	A. Taher et al, "Cyclic Nucleotide Phosphodiesterase Activity in Human Cavernous Smooth Muscle and the Effect of Various Selective Inhibitors", <i>Int. J. Impotence Res.</i> , Vol. 4, Suppl. 2, p.11 (1992)
GX	Yoneda, F. et al, A New Synthesis of Substituted 8-Aminopurine Derivatives, <i>Bulletin of the Chemical Society of Japan</i> , Vol. 46, pp. 1836-1839 (1973).
GY	Yoshisato Takahashi et al, "Pharmacological Effects of Adenosine on Canine Penile Erection", <i>Tohoku J. Exp. Med.</i> , Vol. 165, pp. 49-58 (1991)
GZ	Youssef, S. et al, Purines XIV. [1] Reactivity of 8-Bromo-3,9-dimethylxanthine Towards Some Nucleophilic Reagents, <i>J. Heterocyclic Chem.</i> , 35, 949 (1998).
HA	Harvey C. Taub et al, "Relationship between Contraction and Relaxation in Human and Rabbit Corpus Cavernosum", <i>Urology</i> , Vol. 42, No. 6, pp. 698-704 (Dec. 1993)
HB	W. Joseph Thompson, "Cyclic Nucleotide Phosphodiesterases: Pharmacology, Biochemistry and Function", <i>Pharmac. Ther.</i> , Vol. 51, pp. 13-33 (1991)
HC	Flavio Trigo-Rocha et al, "The Role of Cyclic Adenosine Monophosphate, Cyclic Guanosine Monophosphate, Endothelium and Nonadrenergic, Noncholinergic Neurotransmission in Canine Penile Erection", <i>Journal of Urology</i> , Vol. 149, No. 4, pp. 872-877 (April 1993)
HD	Flavio Trigo-Rocha et al, "Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs", <i>Am. J. Physiol.</i> , Vol. 264, pp. H419-H422 (1993)
HE	Flavio Trigo-Rocha et al, "Intracellular Mechanism of Penile Erection in Monkeys," <i>Neurology and Urodynamics</i> , Vol. 13, pp. 71-80 (1994)
HF	Flavio Trigo-Rocha et al, "The Effect of Intracavernous Injection of Potassium Channel Openers in Monkeys and Dogs," <i>Int. J. of Impotence Research</i> , Smith-Gordon, London, Vol. 7, pp. 41-48 (1995)
HG	Flavio Trigo-Rocha et al, "Sodium Nitroprusside: Physiologic Effects as a Nitric Oxide Donor in Three Species," <i>Int. J. of Impotence Research</i> , Smith-Gordon, London, Vol. 7, pp. 49-56 (1995)
HH	Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Diagnosis and Treatment of Erectile Dysfunction," <i>Urology</i> , Vol. 44, No. 4, pp. 553-556 (Oct. 1994)

1/8/05

Page 6 of 6

<i>CS</i>	HI	Subbarao Vemulapalli et al. "Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor", <i>Journal of Cardiovascular Pharmacology</i> , Vol. 28, pp. 862-869 (1996)
	HJ	Richard J. Weiss, "Effects of Antihypertensive Agents on Sexual Function," <i>Am. Family Physician</i> , Vol. 44, No. 6, pp. 2075-2082 (Dec. 1991)
	HK	E. Douglas Whitehead et al. "Treatment alternatives for impotence", <i>PGM Symposium</i> , Vol. 88, No. 2 pp. 139-149, 152 (August 1990)
	HL	Chackalamannil, Application #09/840,760. Filed 08/28/2001
	HM	Asberom, Application #10/227,778. Filed 08/28/2002
	HN	Asberom, Application #10/290,011. Filed 11/07/2002
<i>CS</i>	HO	PCT International Search Report for PCT US 01/28983 mailed 02/15/2002
	HP	XP-002188426. Synthesis and biological activity of 3-methyl, 7- or 8-alkyl-, 7, 8-dialkyl, heterocyclic, and cyclohexylaminoxanthines, 8001 Chemical Abstracts, Columbus, Ohio, US, No. 106:95677n, (1987).
EXAMINER	<i>Stephen B. Lee</i>	DATE CONSIDERED <i>1/8/05</i>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.